Crystalys is a clinical-stage biopharmaceutical company transforming the treatment of gout. Co-founded by Novo Holdings and Catalys Pacific, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. 
 
Dotinurad, the company’s lead candidate and next-generation URAT1 inhibitor with best-in-class potential for safety and efficacy, is being advanced into global Phase 3 trials as a second-line therapy for gout, supported by extensive clinical data from approvals in multiple Asian markets.

Crystalys Therapeutics

The San Diego office focuses on clinical development and pharmacovigilance to advance innovative healthcare solutions.

San Diego

James Mackay

This department oversees the strategic direction and governance of the organization.

Executive Leadership

This department oversees the planning, execution, and management of clinical trials to advance medical research and ensure regulatory compliance.

Clinical Development

This department oversees regulatory compliance, pharmacovigilance, and quality management within pharmaceutical developments.

Crystalys Therapeutics

Org chart

Teams

Executive Leadership

Clinical Development

Pharmaceutical Affairs

Offices

Crystalys Therapeutics

Org chart

Teams

Executive Leadership

Clinical Development

Pharmaceutical Affairs

Offices

Related companies